{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:46:07Z","timestamp":1793054767800,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.euf.2024.05.011","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T17:01:42Z","timestamp":1716656502000},"page":"231-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape"],"prefix":"10.1016","volume":"10","author":[{"given":"Jason R.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-8668","authenticated-orcid":false,"given":"Vadim S.","family":"Koshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2024.05.011_b0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clgc.2021.08.002","article-title":"Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin","volume":"20","author":"Curran","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euf.2024.05.011_b0010","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/iju.15300","article-title":"Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: a multicenter propensity score-matched study","volume":"30","author":"Taguchi","year":"2023","journal-title":"Int J Urol"},{"issue":"Suppl 7","key":"10.1016\/j.euf.2024.05.011_b0015","doi-asserted-by":"crossref","first-page":"S1346","DOI":"10.1016\/j.annonc.2022.07.1846","article-title":"1768P Clinical outcomes with platinum-based chemotherapy after progression on frontline immunotherapy in metastatic urothelial cancer (mUC)","volume":"33","author":"Szabados","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2024.05.011_b0020","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes","volume":"35","author":"Loriot","year":"2024","journal-title":"Ann Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.euf.2024.05.011_b0025","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1200\/JCO.2023.41.16_suppl.4572","article-title":"Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): analysis of the UNITE study","volume":"41","author":"Jindal","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.euf.2024.05.011_b0030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1200\/JCO.2023.41.6_suppl.523","article-title":"Evaluation of clinical benefit of sacituzumab govitecan (SG) following enfortumab vedotin (EV) in advanced urothelial cancer (UC): real-world experience","volume":"41","author":"Vlachou","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2024.05.011_b0035","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"issue":"4 Suppl","key":"10.1016\/j.euf.2024.05.011_b0040","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2024.42.4_suppl.616","article-title":"Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR2\/3) altered (alt) advanced urothelial cancer (aUC): analysis of UNITE database","volume":"42","author":"Jiang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2024.05.011_b0045","unstructured":"Seagen Inc. A study of disitamab vedotin alone or with pembrolizumab in urothelial cancer that expresses HER2. ClinicalTrials.gov NCT04879329."},{"key":"10.1016\/j.euf.2024.05.011_b0050","unstructured":"BicycleTx Ltd. Study BT8009-100 in subjects with Nectin-4 expressing advanced malignancies. ClinicalTrials.gov NCT04561362."}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924000749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924000749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T08:01:44Z","timestamp":1744531304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456924000749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405456924000749"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2024.05.011","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2024.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}